Actively Recruiting
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Led by Chinese PLA General Hospital · Updated on 2026-04-02
200
Participants Needed
1
Research Sites
339 weeks
Total Duration
On this page
Sponsors
C
Chinese PLA General Hospital
Lead Sponsor
9
940 Hospital of the People's Liberation Army Joint Logistic Support Force
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.
CONDITIONS
Official Title
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 14 to 75 years with relapsed or refractory acute myeloid leukemia diagnosed by 2021 CMA criteria
- Ability to understand and sign informed consent
- Liver function with ALT and AST less than or equal to 2.5 times upper limit of normal and bilirubin less than or equal to 2 times upper limit of normal
- Normal kidney function with creatinine less than or equal to upper limit of normal
- No uncontrolled infections, organ dysfunction, or severe mental illness
- Eastern Cooperative Oncology Group (ECOG) score between 0 and 3 with predicted survival of at least 4 months
- No severe allergic conditions
You will not qualify if you...
- Allergy or contraindication to any study drug
- Pregnant or breastfeeding women
- History of alcohol or drug addiction that may affect treatment compliance
- Mental illness or conditions preventing protocol compliance
- Less than 6 weeks since major surgery
- Liver function with ALT and AST greater than 2.5 times upper limit of normal or bilirubin greater than 2 times upper limit of normal
- Kidney function with creatinine above upper limit of normal
- Poor compliance or substance abuse making participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
D
Daihong Liu, doctor
CONTACT
L
Liping Dou, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here